Article

Desjeux P. Leishmaniasis: current situation and new perspectives

Department of Control, Prevention and Elimination (CDS/CPE), Cluster of Communicable Diseases, World Health Organization (WHO), Avenue Appia, 1211 Geneva 27, Switzerland.
Comparative Immunology Microbiology and Infectious Diseases (Impact Factor: 2.11). 10/2004; 27(5):305-18. DOI: 10.1016/j.cimid.2004.03.004
Source: PubMed

ABSTRACT Leishmaniasis represents a complex of diseases with an important clinical and epidemiological diversity. Visceral leishmaniasis (VL) is of higher priority than cutaneous leishmaniasis (CL) as it is a fatal disease in the absence of treatment. Anthroponotic VL foci are of special concern as they are at the origin of frequent and deathly epidemics (e.g. Sudan). Leishmaniasis burden remains important: 88 countries, 350 million people at risk, 500,000 new cases of VL per year, 1-1.5 million for CL and DALYs: 2.4 millions. Most of the burden is concentrated on few countries which allows clear geographic priorities. Leishmaniasis is still an important public health problem due to not only environmental risk factors such as massive migrations, urbanisation, deforestation, new irrigation schemes, but also to individual risk factors: HIV, malnutrition, genetic, etc em leader Leishmaniasis is part of those diseases which still requires improved control tools. Consequently WHO/TDR research for leishmaniasis has been more and more focusing on the development of new tools such as diagnostic tests, drugs and vaccines. The ongoing effort has already produced significant results. The newly available control tools should allow a scaling up of control activities in priority areas. In anthroponotic foci, the feasibility of getting a strong impact on mortality, morbidity and transmission, is high.

7 Followers
 · 
418 Views
    • "More than 20 species have been described for the Leishmania genus (Desjeux, 2004; Boité et al., 2012). In South America, Leishmania are grouped in two subgenera, Leishmania and Viannia, which cause visceral and cutaneous or mucocutaneous leishmaniasis, respectively (Gramiccia and Gradoni, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Leishmania spp. is a protozoan that maintains its life cycle in domestic and wild animals and it may include bats, a population that has increased in urban environments. This study aimed to investigate the presence of Leishmania spp. in bats captured strictly in urban areas that are endemic for visceral leishmaniasis. The spleen and skin samples of 488 bats from 21 endemic cities in northwestern São Paulo State, Brazil, were tested for the presence of Leishmania kDNA using real-time PCR. Differentiation from Trypanosoma spp. was achieved by amplifying a DNA fragment of the ribosomal RNA gene. The presence of Leishmania spp. kDNA was verified in 23.9% of bats and Trypanosoma spp. DNA was identified in 3.9%. Leishmania species differentiation revealed the presence of L. amazonensis in 78.3% of the bats; L. infantum in 17.4%, and 1 sample (4.3%) showed a mix pattern of L. infantum and L. amazonensis. We also detected, for the first time, L. infantum and L. amazonensis DNA in Desmodus rotundus, the hematophagous bat. The presence of Leishmania spp. DNA in bats strictly from urban areas endemic for visceral leishmaniasis in the State of São Paulo, Brazil indicates that these wild and abundant animals are capable of harboring Leishmania spp. in this new scenario. Due to their longevity, high dispersion capacity and adaptability to synanthropic environments, they may play a role in the maintenance of the life cycle of Leishmania parasites. Copyright © 2015. Published by Elsevier B.V.
    Acta tropica 07/2015; DOI:10.1016/j.actatropica.2015.07.010 · 2.52 Impact Factor
  • Source
    • "through the bite of female sandfly. This disease is characterized by chronic skin lesions and leaves permanent scars as deformation of the infected area [1]. CL is a public health problem with the annual incidence rate of 1.5 million people throughout the world. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study aims to evaluate the in vitro and in vivo antileishmanial activities of Pistacia khinjuk Stocks (Anacardiaceae) alcoholic extract and to compare its efficacy with a reference drug, meglumine antimoniate (MA, Glucantime), against Leishmania tropica and Leishmania major.This extract (0–100 𝜇g/mL) was evaluated in vitro against promastigote and intracellular amastigote forms of L. tropica (MRHO/IR/75/ER) and then tested on cutaneous leishmaniasis (CL) in male BALB/c mice with L. major to reproduce the antileishmanial activity topically. In vitro, P. khinjuk extract significantly (𝑃 < 0.05) inhibited the growth rate of promastigote (IC50 58.6 ± 3.2 𝜇g/mL) and intramacrophage amastigotes (37.3 ± 2.5 𝜇g/mL) of L. tropica as a dose-dependent response. In the in vivo assay, after 30 days of treatment, 75% recovery was observed in the infected mice treated with 30% extract. After treatment of the subgroups with the concentration of 20 and 30% of P. khinjuk extract, mean diameter of lesions was significantly (𝑃 < 0.05) reduced. To conclude, the present investigation demonstrated that P. vera extract had in vitro and in vivo effectiveness against L. major. Obtained findings also provide the scientific evidences that natural plants could be used in the traditional medicine for the prevention and treatment of CL.
    Evidence-based Complementary and Alternative Medicine 02/2015; 2(2):6. DOI:10.1155/2015/149707 · 1.88 Impact Factor
  • Source
    • "Leishmaniasis has a wide spectrum of clinical manifestations, attributable to the different protozoa species belonging to the Leishmania genus (Desjeux, 2004). Cutaneous leishmaniasis first develops as a localized papule, which evolves into an ulcer upon the loss of the epidermis, resulting in skin barrier impairment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stryphnodendron obovatum Benth. is a Brazilian tree used to treat skin ulceration, promote wound healing, and inhibit the growth of protozoa, including Trypanosoma and Leishmania species. Bioguided fractionation of the ethanol extract of S. obovatum stem bark was performed, and antileishmanial and antioxidant activities of the standardized fractions were analyzed. Stationary-phase Leishmania amazonensis promastigotes, murine macrophages, and human red blood cells (RBCs) were exposed to plant extract, standardized fractions or isolated compounds for 48h at 37°C to evaluate their antiparasitic activity and cytotoxicity. The 2,2-diphenyl-1-picryl-hidrazyl assay was used to evaluate antioxidant activity. The S. obovatum extract and fractions showed antileishmanial and antioxidant activity; however, the organic fraction (OF) showed the best efficacy. We identified gallic acid, gallocatechin, epigallocatechin, catechin, and epigallocatechin gallate in the OF fraction. These compounds effectively inhibited L. amazonensis activity, with gallic acid, gallocatechin, and epigallocatechin gallate showing the highest selectivity. Furthermore, the evaluated compounds had no significant effect on murine macrophages and human RBCs. The compounds present in the S. obovatum plant bark ethanol extract may provide an alternative therapeutic approach for L. amazonensis treatment. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Journal of Ethnopharmacology 02/2015; 165. DOI:10.1016/j.jep.2015.02.047 · 3.00 Impact Factor
Show more